Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANESH A ALAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1043227200
CMS profile
1133215
Location
WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$16,767.00

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $16,678.75 2
Food and Beverage $88.25 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $11,218.75 1
Janssen Pharmaceuticals, Inc $5,460.00 1
E.R. Squibb & Sons, L.L.C. $51.03 2
Indivior Inc. $37.22 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANESH A ALAM

NPI 1043227200 · CMS profile ID 1133215

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043227200?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043227200?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043227200?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1043227200?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $16,767.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Indivior Inc. $37.2208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240471427 CMS
Eli Lilly and Company $11,218.7507/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186579282 CMS
E.R. Squibb & Sons, L.L.C. $26.0404/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184784107 CMS
E.R. Squibb & Sons, L.L.C. $24.9902/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184784079 CMS
Janssen Pharmaceuticals, Inc $5,460.0001/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174461560 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,495.83 24
PY2020 $2,250.00 4
PY2024 $1,068.69 8
PY2025 $16,767.00 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,292.36 12
PY2025 Principal investigator $131,175.91 17
PY2024 Principal investigator $333,688.72 94
PY2023 Principal investigator $642,167.72 100
PY2022 Principal investigator $346,465.71 57
PY2021 Principal investigator $149,586.53 50
PY2020 Principal investigator $478,016.95 67
PY2019 Recipient $1,282.88 8
PY2019 Principal investigator $534,507.18 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $141.72 12/31/2022 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH PRACTICE
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features No dispute reported 06/30/2026 889828457
Principal investigator 1 ITI, Inc. $12,485.85 12/23/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369369
Principal investigator 1 ITI, Inc. $7,782.62 12/23/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369375
Principal investigator 1 Indivior Inc. $3,235.00 12/21/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498631
Principal investigator 1 Janssen Research & Development, LLC $19,130.00 12/19/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266687
Principal investigator 1 Indivior Inc. $2,476.00 12/14/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498551
Principal investigator 1 Indivior Inc. $1,194.18 12/12/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498487
Principal investigator 1 Indivior Inc. $2,420.00 12/06/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498399
Principal investigator 1 Indivior Inc. $7,071.00 12/01/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498325
Principal investigator 1 ITI, Inc. $7,061.39 11/25/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369115
Principal investigator 1 ITI, Inc. $2,824.82 11/25/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369121
Principal investigator 1 Indivior Inc. $1,735.00 11/15/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498197
Principal investigator 1 Indivior Inc. $766.13 11/14/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498157
Principal investigator 1 Indivior Inc. $1,280.00 11/08/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498099
Principal investigator 1 Indivior Inc. $9,324.00 11/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917498033
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 10/31/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266679
Principal investigator 1 Janssen Research & Development, LLC $53.00 10/31/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266681
Principal investigator 1 ITI, Inc. $4,909.99 10/28/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368885
Principal investigator 1 ITI, Inc. $8,974.33 10/28/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368891
Principal investigator 1 Janssen Research & Development, LLC $9,080.00 10/28/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266685
Principal investigator 1 Indivior Inc. $5,761.00 10/18/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497929
Principal investigator 1 Indivior Inc. $764.16 10/13/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497893
Principal investigator 1 Janssen Research & Development, LLC $5,627.00 10/10/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266683
Principal investigator 1 Indivior Inc. $2,403.00 10/07/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497813
Principal investigator 1 ITI, Inc. $4,485.38 09/30/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368729
Principal investigator 1 Indivior Inc. $3,487.00 09/28/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497723
Principal investigator 1 Indivior Inc. $6,457.00 09/20/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497633
Principal investigator 1 Indivior Inc. $18,964.00 09/07/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497555
Principal investigator 1 Janssen Research & Development, LLC $24,007.00 09/05/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266677
Principal investigator 1 ITI, Inc. $4,433.29 09/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368553
Principal investigator 1 Alkermes, Inc. $500.00 08/26/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder No dispute reported 06/30/2026 902758055
Principal investigator 1 ITI, Inc. $3,975.56 08/26/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368469
Principal investigator 1 Indivior Inc. $1,140.00 08/23/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497483
Principal investigator 1 Indivior Inc. $1,596.57 08/22/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497459
Principal investigator 1 Indivior Inc. $11,353.00 08/17/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497421
Principal investigator 1 Indivior Inc. $5,743.00 08/09/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497379
Principal investigator 1 Janssen Research & Development, LLC $29,537.00 08/09/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266675
Principal investigator 1 Janssen Research & Development, LLC $53.00 08/08/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266673
Principal investigator 1 Alkermes, Inc. $1,243.00 08/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder No dispute reported 06/30/2026 902757873
Principal investigator 1 ITI, Inc. $9,034.46 08/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368265
Principal investigator 1 Indivior Inc. $1,490.00 08/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497295
Principal investigator 1 Indivior Inc. $672.24 07/11/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917497221
Principal investigator 1 Janssen Research & Development, LLC $53.00 07/11/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266671
Principal investigator 1 Janssen Research & Development, LLC $8,896.00 06/27/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266669
Principal investigator 1 ITI, Inc. $2,936.92 06/24/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368007
Principal investigator 1 Janssen Research & Development, LLC $48,117.00 05/30/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266665
Principal investigator 1 Janssen Research & Development, LLC $9,225.00 05/23/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266663
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 05/23/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885266667
Principal investigator 1 Indivior Inc. $1,350.00 05/05/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496771
Principal investigator 1 Indivior Inc. $765.58 05/02/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496693
Principal investigator 1 Indivior Inc. $1,140.00 04/13/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496559
Principal investigator 1 Indivior Inc. $1,385.00 03/31/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496529
Principal investigator 1 Indivior Inc. $7,233.00 03/17/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496481
Principal investigator 1 Allergan, Inc. $8,690.70 03/08/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 864373775
Principal investigator 1 Alkermes, Inc. $85.00 02/14/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 902758141
Principal investigator 1 ITI, Inc. $9,250.00 01/28/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952366919
Principal investigator 1 Indivior Inc. $466.82 01/27/2022 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 917496361